Imricor Medical Systems (IMR) investor relations material

Opening remarks and agenda

• Meeting opened with introductions of directors, CFO, audit representative, and company secretary, confirming a quorum was present and business could proceed.

• Shareholders, proxies, and CDI holders were welcomed, with voting and question procedures explained.

Financial performance review

• 2025 was highlighted as a defining year, with progress in clinical, regulatory, commercial, and operational priorities.

• Achievements included advancing the U.S. regulatory pathway, progress in the VISABL-AFL clinical trial, and the world's first ventricular tachycardia ablation in the MR environment.

• Expansion in Europe continued, with technology adoption in leading centers and growing recognition of the platform approach.

• Entered the next phase with a stronger balance sheet, enabling disciplined investment in commercial capabilities, regulatory approvals, and clinical trials.

Board and executive committee updates

• Steve Wedan serves as President, CEO, and Board Chair, with Mark Tibbles as Deputy Chair and Lead Independent Director, and several non-executive directors including Peter McGregor, Anita Messal, Jonathon Gut, Jeffrey Leighton, and Aldo Denti, with Jeffrey Leighton as CFO.

• Directors Mark Tibbles, Anita Messal, Peter McGregor, and Aldo Denti were introduced, along with CFO Jonathon Gut and audit firm representative Jeff Ostapik.